Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

株式のランク #3272
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
株価
$118.49
最終同期: 2026-10-16
時価総額
$5.39B
変化(1日)
-2.43%
変化(1年)
135.75%
国
US
取引 Haemonetics Corporation (HAE)

カテゴリー

Healthcare
Haemonetics Corporation(HAE)の営業利益率
October 2026 時点の営業利益率 TTM: 18.18%
Haemonetics Corporation の最新の財務報告と株価によると、現在の営業利益率(TTM)は 18.18% です。2024 年末時点では 12.60% でした。
Haemonetics Corporation の営業利益率の履歴(2000 から 2026)
各年末の営業利益率
年 営業利益率 変化
2026 (TTM) 18.18% 11.53%
2025 16.30% 29.37%
2024 12.60% -5.62%
2023 13.35% 64.21%
2022 8.13% 22.07%
2021 6.66% -57.23%
2020 15.57% 80.42%
2019 8.63% 38.97%
2018 6.21% -383.56%
2017 -2.19% -54.75%
2016 -4.84% -208.76%
2015 4.45% -11.71%
2014 5.04% -20.38%
2013 6.33% -48.07%
2012 12.19% -25.40%
2011 16.34% 26.67%
2010 12.90% -9.85%
2009 14.31% 5.14%
2008 13.61% -2.51%
2007 13.96% -40.82%
2006 23.59% 50.93%
2005 15.63% 24.05%
2004 12.60% 13.31%
2003 11.12% -2.37%
2002 11.39% 149.23%
2001 4.57% -62.23%
2000 12.10% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差 国
17.03% -99.06%
US
17.86% -99.02%
IE
22.03% -98.79%
US
21.46% -98.82%
US
0.00% -
DE
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。